ERBB2 and breast cancer: Altunay et al. (2023) performed SPET/CT imaging with a 99mTc-labeled single-domain antibody (RAD201) in six patients with HER2-positive breast cancer and found that the tracer was able to discriminate HER2 status in advanced breast cancer, regardless of ongoing HER2-targeted antibody treatment.